48
Hans Loibner, Chief Executive Officer of the 11-year-old Viennese biotech, said: “Our recent achievement of obtaining the EU marketing authorisation for our most advanced project in combination with access to additional funding through the EIB forms a very promising basis for our company’s future.”
The investment of the EIB will fuel the development of cancer pipeline of Apeiron Biologics, which already markets an antibody drug (dinutuximab beta, APN311) that targets the GD2 antigen highly expressed by the rare pediadric cancer neuroblastoma in Europe Most recently, the antibody has been licenced for FDA registration. Further clincical…